Clinical Trials
7 trialsNCT00248287 2025-01-29
CA225200
US Oncology Research
Phase 2 Active not recruiting
NCT01097642 2021-09-22
ICE
The Methodist Hospital Research Institute
Phase 2 Completed
NCT02318901 2019-10-21
PembroMab
Western Regional Medical Center
Phase 1/2 Terminated
NCT00232505 2017-06-28
Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01451632 2016-09-08
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
Phase 1 Completed
NCT00633464 2016-03-10
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
R-Pharm
Phase 2 Completed
NCT00463788 2014-02-13
BALI-1
Merck KGaA, Darmstadt, Germany
Phase 2 Completed